Burton Eisenberg - Concepedia

Author

Burton Eisenberg

Also Known As

B EISENBERG, B Eisenberg, B L Eisenberg, B. Eisenberg, B. L. EISENBERG, B. L. Eisenberg, B.L. Eisenberg, Burton Eisenberg, Burton L Eisenberg, Burton L. Eisenberg

227

Publications

17.5K

Citations

H-Index

101

Concepts

All Affiliations

Fox Chase Cancer Center Dartmouth–Hitchcock Medical Center Temple University Dana-Farber Cancer Institute Dartmouth College

About

Burton Eisenberg is an author at Fox Chase Cancer Center specializing in medicine, oncology, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	58	4.3K
2	Health Sciences	15	19	767
3	Biochemistry	4	4	368
4	Law	1	1	19
5	Biomolecular Engineering	1	1	279

Burton Eisenberg

Publications

16.1K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri, Margaret von Mehren, Charles D. Blanke, New England Journal of Medicine	2002	4.4K
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Journal of Clinical Oncology	2003	2.3K
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i> Charles D. Blanke, George D. Demetri, Margaret von Mehren, Journal of Clinical Oncology	2008	1K
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors Michael C. Heinrich, Christopher L. Corless, Charles D. Blanke, Journal of Clinical Oncology	2006	808
Soft tissue sarcomas of adults: state of the translational science. Ernest C. Borden, Laurence H. Baker, Robert S. Bell, PubMed Single Gene FamilyImatinib MesylateGastrointestinal OncologyMedicineTranslational Science	2003	616
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 Burton Eisenberg, Jonathan Harris, Charles D. Blanke, Journal of Surgical Oncology	2008	417
Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation Nancy B. Kuemmerle, Evelien Rysman, Portia S. Lombardo, Molecular Cancer Therapeutics Metabolic SyndromeLipid SynthesisLipid MetabolismBiochemistryMedicine	2011	279
Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial Dian Wang, Qiang Zhang, Burton Eisenberg, Journal of Clinical Oncology	2015	279
Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514 William Kraybill, J. Harris, Ira J. Spiro, Journal of Clinical Oncology	2006	275
Tumor Cell-Specific <b> <i>BRCA1</i> </b> and <b> <i>RASSF1A</i> </b> Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients Inmaculada Ibañez de Cáceres, Cristina Battagli, Manel Esteller, Cancer Research	2004	273

Page 1